Clinical Question: As compared to placebo, does the angiotensin-II-receptor agonist (ARB) losartan delay progression to ESRD and improve mortality in patients with type 2 diabetes and nephropathy?
No Url Found
Login
Log in below to access learning modules.
Forgot Password
Enter your email address or username and we’ll send you instructions to reset your password.